CPC's MicroCNX Series Connectors Receive Top Biopharma Industry Honor

News provided by

Dec 07, 2022, 16:15 ET

DOWNERS GROVE, Ill., Dec. 7, 2022 /PRNewswire/ -- CPC (Colder Products Company), part of Dover (NYSE: DOV) and a leading manufacturer of connection technologies used in biopharmaceutical processing, today announced that its MicroCNX^® Series Connectors were named a 2022 Pharma Innovation Award winner. The award recognizes advancements in product quality and manufacturing efficiency.

Ultra-compact sterile MicroCNX connectors provide biopharmaceutical and cell and gene therapy (CGT) manufacturers with a much-needed alternative to tube welding for their small-volume closed aseptic processes. They are the industry's first aseptic connectors designed to provide a simple, efficient method of connecting tubing in small-format assemblies.

Testing indicates that making a sterile connection with the new connector is up to four times faster than an operator using a tube welder.¹ MicroCNX connectors require minimal training and only three steps to make a connection. In contrast, tube welding involves a dozen or more steps. Operator challenges also include maneuvering the tube welder into position, dealing with equipment maintenance, and requiring precise technique to create a successful weld. With MicroCNX solutions, there is no risk of faulty welds, welder breakdowns, or production delays due to weld equipment downtime.

"MicroCNX connectors make sterile closed connections of very small-bore tubing in an easier, faster way than tube welding," said Troy Ostreng, Senior Product Manager for CPC's biopharmaceutical business. "It's great that both customers and the industry view MicroCNX connectors as a key innovation for bioprocessing, cell therapy and gene therapy workflows."

This most recent accolade from Pharma Manufacturing adds to others designating the MicroCNX series as a top global innovation in biopharmaceutical processing. Earlier this year, MicroCNX connectors claimed a Medicine Maker Innovation Award, which recognizes "the highest-impact pharmaceutical development and manufacturing technologies."

1. Data on file.

About CPC:
CPC (Colder Products Company) is the leader in single-use connection technology, offering a wide variety of connectors for biopharmaceutical manufacturing. The company's innovative, flexible products enable users to easily combine multiple components and systems including process containers, tubing manifolds, transfer lines, bioreactors and other bioprocess equipment. Robust single-use connectors maintain media sterility and integrity while improving production yields, decreasing time to market and reducing costs. The company's well-known AseptiQuik^® connectors provide quick and easy sterile connections even in non-sterile environments. Learn more at cpcworldwide.com/bio. Connect with confidence with CPC, an operating company within Dover Corporation.

About Dover:
Dover is a diversified global manufacturer and solutions provider with annual revenue of over $8 billion. We deliver innovative equipment and components, consumable supplies, aftermarket parts, software and digital solutions, and support services through five operating segments: Engineered Products, Clean Energy & Fueling, Imaging & Identification, Pumps & Process Solutions and Climate & Sustainability Technologies. Dover combines global scale with operational agility to lead the markets we serve. Recognized for our entrepreneurial approach for over 65 years, our team of over 25,000 employees takes an ownership mindset, collaborating with customers to redefine what's possible. Headquartered in Downers Grove, Illinois, Dover trades on the New York Stock Exchange under "DOV." Additional information is available at dovercorporation.com.

CPC Contact:
Jana Stender
(612) 564-2053
[email protected]

Dover Media Contact:
Adrian Sakowicz, VP, Communications
(630) 743-5039
[email protected]

Dover Investor Contact:
Jack Dickens, Senior Director, Investor Relations
(630) 743-2566
[email protected]

SOURCE Dover